Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye DiseaseBusiness Wire • 09/29/20
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in ChildrenBusiness Wire • 09/10/20
Ocular Therapeutix™ Announces Successful Resolution of FDA Warning Letter Related to ReSure® SealantBusiness Wire • 09/08/20
Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular InsertsBusiness Wire • 09/04/20
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business UpdateBusiness Wire • 08/07/20
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/29/20
Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular InsertsBusiness Wire • 07/23/20
Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)Business Wire • 07/17/20
Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular InsertsBusiness Wire • 07/15/20
Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/13/20
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/27/20
Ocular Therapeutix: Multiple Upside Drivers For This Platform Technology PlaySeeking Alpha • 01/21/20